by R127W-HNF-4a. The decreased expression of HNF-1a and PKL genes could contribute to the beta-cell dysfunction that characterises HNF-4a diabetes.
Methods
Plasmid constructs. We generated R127W and Q268X-HNF4a cDNAs using the Chameleon Double-Stranded Mutagenesis Kit (Stratagene, La Jolla, Calif., USA) and subcloned them into pcDNA3.1 (Invitrogen, Carlsbad, Calif., USA). The nucleotide sequence encoding the FLAG epitope (DY-KDDDDK) was introduced in the frame at the C-termini of the wild-type (WT) and R127W sequences. The CD1b-HNF4a mutant is a C-terminal truncated mutant retaining the DNA binding ability [6] . It was generated as described previously [6] . Human HNF-1a gene promoter (nucleotides ±129 to 196) was subcloned into pGL3-basic vector (Promega, Madison, Wis., USA). The promoter region between positions ±206 and ±7 of the rat PKL gene including the HNF-4a binding site was amplified by PCR and subcloned into pGL3-basic vector. The sequence of each construct was verified. We inserted eight copies of the HNF-4a binding site of the mouse transthyretin promoter upstream of the HSV-TK promoter/luciferase fusion gene (pHNF4-tk-Luc). The CBP expression vector, pRc/RSV-CBP, has been described previously [4] .
Cell culture and transient transfection assays. We maintained HeLa and MIN6 cells in D-MEM supplemented with 10 % and 15 % fetal bovine serum, respectively. We used MIN6 cells in experiments between passages 7 to 12. When reaching 80 % confluence, HeLa and MIN6 cells were detached and plated in 6-well plates at a density of 1.5´10 5 (HeLa) or 3´10
5
(MIN6) cells per well. Cells were transfected for 3 h in serumfree OPTI-MEMI (Life Technologies, Rockville, Md., USA) with the indicated amounts of the expression vectors (Fig. 2  legend) and 0.5 mg of the reporter genes together with 10 ng of pRL-SV40, the internal control plasmid (Promega), using the LipofectAMINE PLUS Reagent (Life Technologies) according to the manufacturer's protocol. After another 48-h incubation, luciferase activity was measured.
Immunolocalisation of HNF-4a in transfected cells. The HeLa cells (1´10 5 ) grown on Lab-Tek chamber slides (Nalge Nunc, Naperville, Ill., USA) were transfected with 0.5 mg of FLAGepitope-tagged WT and R127W-HNF-4a constructs. After 48 h, cells were fixed with 4 % paraformaldehyde for 10 min at 4°C and blocked with Block Ace (Yukijirushi, Sapporo, Japan) for 40 min at room temperature. Cells were incubated with mouse anti-FLAG monoclonal antibody (Sigma, St. Louis, Mo., USA) for 12 h at 4°C, followed by incubation with biotinylated horse anti-mouse IgG (Vector, Burlingame, Calif., USA) and fluorescein avidin D (Vector). Nuclei were made visible with propidium iodide (PI).
Electrophoretic mobility shift assay (EMSA) and western blot analysis. We used in vitro translated proteins or nuclear cell extract. Wild-type and mutant HNF-4a proteins were synthesised using 1 mg of pcDNA3.1 construct and TNT T7 Transcription/Translation System (Promega). We transfected HeLa cells (1´10 6 ) with 8 mg of WT or mutant HNF-4a and nuclear extracts were prepared as described [7] . We used 2 ml of the in vitro translated proteins or 3 mg of nuclear proteins for EMSA. Proteins were incubated with 32 P-labelled oligonucleotide containing the HNF-4a binding site of the human HNF-1A promoter (5 ¢-GGCTGAAGTCCAAAGTT-CAGTCCCTTCGC-3 ¢) in a 20 ml reaction mixture containing 20 mmol/l HEPES (pH 7.9), 75 mmol/l KCl, 3 % Ficoll, 1 mmol/l MgCl 2 , 0.1 mmol/l EDTA, 1 mmol/l dithiothreitol (DTT), 2 mg poly (dI-dC) at 25°C for 30 min. The DNA-protein complexes were analysed on 5 % polyacrylamide gels using 0.5´TRIS-borate/EDTA before (TBE) buffer. The polyclonal antibody (a445) [2] was obtained from Dr F. M. Sladek (University of California). The images were quantified using ScanningImager (Molecular Dynamics, Sunnyvale, Calif., USA). Western blot analysis was done using anti-HNF-4a antibody (Santa Cruz Biotechnology, Santa Cruz, Calif., USA) [7] .
Results
Subcellular localisation of wild-type and mutant HNF-4a. We transfected HeLa cells with FLAG tagged WT-HNF-4a and R127W-HNF-4a constructs ( Fig. 1a-d ). Out of 133 cells 18 (13.5 %) and out of 143 cells 17 (11.9 %) were positive for staining, respectively. Immunostaining suggested that both WT-HNF-4a and R127W-HNF-4a were localised in the nucleus. The nuclear localisation of both proteins was confirmed by the nuclear staining with PI ( Fig. 1 c, d ), indicating that this mutation does not affect the intracellular localisation.
DNA binding study. We carried out EMSA using in vitro translated HNF-4a. The expressions of WT, R127W and CD1b-HNF-4a translated in vitro were similar (Fig. 1 e) . The WT-HNF-4a construct bound to the oligonucleotide and the binding was blocked by the addition of 50-fold excess of unlabelled probes ( Fig. 1 f, lanes 1 and 2) . The DNA-protein complex was supershifted by the addition of the polyclonal anti-HNF-4a antiserum, but normal serum did not affect the complex (lanes 3 and 4). The binding of R127W-HNF-4a was decreased by 47.0 % compared with that of WT-HNF-4a (lanes 1 and 5).
Equal amounts of WT and CD1 b or R127W and CD1 b proteins were mixed and assayed for DNA binding. An additional protein/DNA complex was observed with an intermediate mobility (lanes 7 and 8). These results suggest that R127W-HNF-4a forms a homodimer and heterodimer.
We also carried out EMSA using nuclear extracts from HNF-4a transfected HeLa cells. We confirmed that the expression level of WT-HNF-4a and R127W-HNF-4a was the same by western blot analysis (Fig. 1 g) . We found WT-HNF-4a specifically bound to the oligonucleotide as described above (Fig. 1 h,  lanes 1±4 ) but Q268X-HNF-4a failed to bind to the oligonucleotide (Fig. 1 h, lane 6) as noted previously [8] . The binding of R127W-HNF-4a was decreased by 61.7 % compared with that of WT-HNF-4a (lanes 1 and 5). These data suggest that the R127W mutation affects the DNA binding ability of HNF-4a.
Transactivation study. The transactivation ability of WT and mutant HNF-4a was studied in HeLa cells that lack endogenous HNF-4a activity. We fond WT-HNF-4a stimulated the transcription of the HNF-1a and PKL promoter-luciferase reporter constructs and generated a statistically significant increase in the reporter gene activity whereas Q268X-HNF-4a did not (Fig. 2 a, b) . The transactivation activity of R127W-HNF-4a was 70.3 % (p = 0.0072) (HNF-1a) and 73.5 % (p = 0.0045) (PKL) of that of WT-HNF4a. A reporter construct with a heterologous TK promoter and HNF-4a binding sequence as an enhancer (pHNF4-tk-Luc) was also used to confirm the impaired transactivation activity of R127W-HNF-4a. The transactivation activity of R127W-HNF-4a was decreased by 66.2 % (p = 0.001) compared with WT-HNF-4a (Fig. 2 c) suggesting that R127W-HNF-4a represents a loss-of-function mutation.
The transactivation activity of R127W-HNF-4a was further investigated using MIN6 cells, an insulin secreting cell line that has endogenous HNF-4a activity. The transcription of HNF-1a, PKL and heterologous TK reporters by R127W-HNF-4a were reduced compared with WT-HNF-4a: 77.7 % (p = 0.033), 77.8 % (p = 0.0075) and 48.2 % (p = 0.002), respectively (Fig. 2 d, e and f) .
Because R127W is located in a region of HNF-4a that interacts with the coactivator CBP, this mutation could impair the functional interaction of HNF-4a with CBP. Co-transfection of HNF-4a and CBP constructs stimulated the pHNF4-tk-Luc reporter gene activity by 4.0-fold compared with the transfection of HNF-4a alone. The CBP construct also increased the transcriptional activity of R127W-HNF-4a by 4.7-fold (Fig. 2 g) , suggesting that there is no impaired synergy between R127W-HNF-4a and CBP in the system.
Discussion
We have previously shown that mutations in the MODY3/HNF-1a gene result in diverse functional consequences including impairment of DNA binding ability, improper intracellular localisation and reduced transcriptional activity [7] . In this study, we have shown that the nuclear import and functional synergy with CBP of R127W-HNF-4a are normal and the DNA binding and the transactivation ability of this mutation are reduced. Impairment of the synergistic effect between another missense mutation (E276Q-HNF-4a) and COUP-TFII on the transcription of HNF-1a has been reported [9] . The decreased binding ability of R127W-HNF-4a suggests the conserved arginine residue is important for the binding. The decreased binding ability of R127W-HNF-4a might account for its reduced transactivation activity. The R127W mutation was present in 3 out of 5 of the diabetic patients we examined (in total 4 because subject II-2 can be assumed to have the R127W mutation) [3] (Fig. 2 h) . The age at diagnosis of the diabetic patients with the mutation ranged from 17±90 years [3] . Such a variable penetrance of the mutant allele could be a consequence of the relatively mild nature of this mutation. There were two affected members who did not have the mutation (III-3 and III-6). They could have another form of Type II diabetes because diabetes was transmitted from both parents. Such aetiological heterogeneity has been noted previously [10] .
It has recently been reported that the transactivation activity of R127W-HNF-4a is normal and sug- gested that this mutation is a rare polymorphism [5] . Our results suggest otherwise. We do not have an adequate explanation to account for the difference. That study used two reporter constructs; pZLHIV-A1±4 which contains four HNF4 binding sites of the apolipoprotein A1 upstream of an HIV-LTR basal promoter and pLZ100 which contains apolipoprotein CIII promoter containing one HNF4 binding site. It is known that HNF-4a activity depends on the promoter context [6] . The difference of the reporter systems might have contributed to the different results.
The transcription of the HNF-1a and PKL genes by R127W-HNF-4a were decreased. The HNF-1a transcription factor regulates the expression of genes involved in the glucose homeostasis (e. g. GLUT2, PKL and insulin) in pancreatic beta-cells [7] . Thus, the mechanism by which R127W-HNF-4a leads to beta-cell dysfunction could be through HNF-1a both directly and indirectly. Identification of the target genes of HNF-4a action in the beta cell should lead to a better understanding of the molecular pathogenesis of MODY1/HNF-4a diabetes.
